Table 1.
Cohort Characteristics
| n=123 | |
|---|---|
| Median age, years (IQR) | 68 (12) |
| Men (%) | 68 (55%) |
| Race (%) | |
| White | 112 (91%) |
| Black | 1 (0.81%) |
| Asian | 5 (4.1%) |
| Native Hawaiian/Pacific Islander | 1 (0.81%) |
| American Indian/Alaska Native | 4 (3.3%) |
| Comorbid conditions (%) | |
| Hypertension | 79 (64%) |
| Coronary artery disease | 31 (25%) |
| Congestive heart failure | 4 (3.3%) |
| Cerebrovascular disease | 6 (4.9%) |
| Peripheral vascular disease | 9 (7.3%) |
| Chronic obstructive pulmonary disease | 43 (35%) |
| Pulmonary hypertension | 4 (3.3%) |
| Diabetes mellitus | 24 (20%) |
| Smoking status (%) | |
| Former | 78 (63%) |
| Current | 26 (21%) |
| Never | 19 (16%) |
| Median pack-yearsa (IQR) | 40 (34) |
| Median FEV1, % predicted (IQR) | 81 (32) |
| Missing (%) | 8 (6.5%) |
| Median Diffusing capacity of the lung for carbon monoxide, % predicted (IQR) | 67 (25) |
| Missing (%) | 15 (12%) |
| Clinical Stage (%) | |
| Stage IA | 57 (46%) |
| Stage IB | 16 (13%) |
| Stage IIA | 18 (15%) |
| Stage IIB | 5 (4.1%) |
| Stage IIIA | 21 (17%) |
| Stage IIIB | 6 (4.9%) |
| Invasive mediastinal staging (%) | |
| None | 17 (14%) |
| Mediastinoscopy | 86 (70%) |
| Endobronchial ultrasound | 8 (6.5%) |
| Endobronchial ultrasound/mediastinoscopy | 12 (9.8%) |
| Final diagnosis (%) | |
| NSCLC | 112 (90%) |
| Small cell lung cancer | 1 (0.81%) |
| Metastasis (non-lung primary) | 4 (3.3%) |
| Infection | 2 (1.6%) |
| Benign lesion | 4 (3.3%) |
| Final Pathologic Stage b (%) | |
| Stage 0 | 1 (0.89%) |
| Stage IA | 39 (35%) |
| Stage IB | 31 (28%) |
| Stage IIA | 9 (8.0%) |
| Stage IIB | 7 (6.3%) |
| Stage IIIA | 23 (21%) |
| Stage IIIB | 2 (1.8%) |
| Prevalence of nodal disease b (%) | |
| N0 | 81 (72%) |
| N1 | 11 (9.8%) |
| N2 | 18 (16%) |
| N3 | 2 (1.8%) |
Interquartile range (IQR), Non-small cell lung cancer (NSCLC), Maximum standard uptake value (SUVMax), Vascular endothelial growth factor-C (VEGF-C), Forced expiratory volume in the first second (FEV1),, Fluorodeoxyglucose (FDG).
a
Among smokers.
b
Among 112 patients with confirmed NSCLC